SER-287
- Generic Name
- SER-287
- Drug Type
- Biotech
- Background
SER-287 comprises healthy microbiome-derived Gram positive bacterial spores.
A Study to Assess Efficacy and Safety of SER-287 in Adults With Active Mild-to-Moderate Ulcerative Colitis
Phase 2
Terminated
- Conditions
- Ulcerative Colitis
- Interventions
- Drug: Placebo for Vancomycin Pre-Treatment
- First Posted Date
- 2018-11-29
- Last Posted Date
- 2022-08-12
- Lead Sponsor
- Seres Therapeutics, Inc.
- Target Recruit Count
- 203
- Registration Number
- NCT03759041
- Locations
- 🇨🇦
(Investigator site), Saskatoon, Saskatchewan, Canada
A Study to Evaluate the Safety, Tolerability and Microbiome Dynamics of SER-287 in Subjects With Mild-to-Moderate Ulcerative Colitis
Phase 1
Completed
- Conditions
- Ulcerative Colitis
- Interventions
- First Posted Date
- 2015-12-01
- Last Posted Date
- 2019-06-20
- Lead Sponsor
- Seres Therapeutics, Inc.
- Target Recruit Count
- 58
- Registration Number
- NCT02618187
- Locations
- 🇺🇸
Community Clinical Research Network, Marlborough, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath